Auven’s ADC Therapeutics raises $80m

Further funding was provided by UK-based pension scheme Astra Zeneca, as well as other investors from Europe and the US.

The company will use the fresh capital to expand its product portfolio and to fund a collaboration with Astra Zeneca's biologics research arm Med Immune.

Previous funding
Auven, then known as Celtic Therapeutics, launched ADC with $50m of capital in March 2012.

In October 2013, Auven, together with Med Immune, injected another $40m.

Company
Founded in 2012 and based in Lausanne, Switzerland, ADC Therapeutics is an oncology drug development company that specialises in the development of proprietary antibody drug conjugates (ADCs), targeting major solid and blood cancers. ADC works in laboratories in London and San Francisco.

People
Chris Martin is the CEO of ADC. Peter Corr is managing general partner at Auven and chairman of the board of ADC.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Expansion
• Healthcare
• Switzerland